TBPH vs VTRS
TBPH: A commercial-stage biopharmaceutical company with an FDA-approved COPD inhalation therapy under review for strategic alternatives following a failed neurology pipeline program. VTRS: A global pharmaceutical giant supplying over 1 billion patients annually with generics, branded medicines, and an expanding innovative pipeline across more than 165 countries.
Side-by-side fundamentals
| Metric | TBPH | VTRS | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $16.81 | $17.01 | |
| Market cap as of 2026-07-23 | $873M | $20.0B | |
| P/E as of 2026-07-23 | 7.62 | n/a | |
| PEG as of 2026-07-23 | n/a | 1.44 | |
| Net margin as of 2026-07-23 | +104.3% | -2.0% | TBPH higher |
| Gross margin as of 2026-07-23 | +100.0% | +39.8% | TBPH higher |
| Operating margin as of 2026-07-23 | +46.8% | +0.3% | TBPH higher |
| ROE as of 2026-07-23 | +43.9% | -2.0% | TBPH higher |
| ROA as of 2026-07-23 | +25.5% | -0.8% | TBPH higher |
| Debt / equity as of 2026-07-23 | 0.11 | 0.98 | TBPH lower |
| Revenue growth (YoY) as of 2026-07-23 | +68.2% | +1.6% | TBPH higher |
| Revenue CAGR (3y) SEC XBRL | +27.9% | -4.2% | TBPH higher |
| Dividend yield as of 2026-07-23 | n/a | +2.8% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-07-23 | 0.25 | 0.91 | |
| 1-year return as of 2026-07-22 close | +49.7% | +84.1% | VTRS higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.